COMP <GO>
MNKD vs AVLN // EV/EBITDA & P/E VALUATION
MannKind Corporation (NASDAQ) VS. Avalyn Pharma Inc. (NASDAQ) • 15-METRIC TALLY: MNKD 1
— AVLN 1
■ METRIC PARITY
LAST: $3.50 (+2.04%) • MKT CAP: $1.13B
valuation
24.6x
LAST: $25.71 (-0.12%) • MKT CAP: $1.14B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MNKD VS. AVLN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MNKD | AVLN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 92.30% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 54.50% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 24.6x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.22% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | 11.10% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | 1.70% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 22.20% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.6 | 44.2 | +11.40 | MNKD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.13B | $1.14B | -$14.4M | AVLN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MNKD REV | AVLN REV | MNKD GROSS % | AVLN GROSS % | MNKD FCF | AVLN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $349.0M | $0 | 92.3% | — | $13.7M | — |
| FY 2024 | $285.5M | — | 93.9% | — | $32.8M | — |
| FY 2023 | $199.0M | — | — | — | $34.1M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MNKD // BETA —
AVLN // BETA —